PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

被引:51
|
作者
Irwin, Christopher P. [1 ]
Portorreal, Yasiri [1 ]
Brand, Christian [1 ]
Zhang, Yachao [1 ]
Desai, Pooja [1 ]
Salinas, Beatriz [1 ]
Weber, Wolfgang A. [2 ,3 ]
Reiner, Thomas [1 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, Radiochem & Imaging Sci Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Imaging & Nanotechnol, New York, NY 10065 USA
来源
NEOPLASIA | 2014年 / 16卷 / 05期
关键词
RESECTION; SURVIVAL; GLIOMA; EXTENT; EXPRESSION; OLAPARIB; GUIDANCE; SURGERY;
D O I
10.1016/j.neo.2014.05.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New intravital optical imaging technologies have revolutionized our understanding of mammalian biology and continue to evolve rapidly. However, there are only a limited number of imaging probes available to date. In this study, we investigated in mouse models of glioblastoma whether a fluorescent small molecule inhibitor of the DNA repair enzyme PARP1, PARPi-FL, can be used as an imaging agent to detect glioblastomas in vivo. We demonstrated that PARPi-FL has appropriate biophysical properties, low toxicity at concentrations used for imaging, high stability in vivo, and accumulates selectively in glioblastomas due to high PARP1 expression. Importantly, subcutaneous and orthotopic glioblastoma xenografts were imaged with high contrast clearly defining tumor tissue from normal surrounding tissue. This research represents a step toward exploring and developing PARPi-FL as an optical intraoperative imaging agent for PARP1 in the clinic.
引用
收藏
页码:432 / 440
页数:9
相关论文
共 37 条
  • [21] PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study
    Pignochino, Ymera
    Crisafulli, Giovanni
    Giordano, Giorgia
    Merlini, Alessandra
    Berrino, Enrico
    Centomo, Maria Laura
    Chiabotto, Giulia
    Brusco, Silvia
    Basirico, Marco
    Maldi, Elena
    Pisacane, Alberto
    Leuci, Valeria
    Sangiolo, Dario
    D'Ambrosio, Lorenzo
    Aglietta, Massimo
    Kasper, Bernd
    Bardelli, Alberto
    Grignani, Giovanni
    CANCERS, 2021, 13 (24)
  • [22] The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
    Huang, Jing
    Wang, Lei
    Cong, Zhongyi
    Amoozgar, Zohreh
    Kiner, Evgeny
    Xing, Deyin
    Orsulic, Sandra
    Matulonis, Ursula
    Goldberg, Michael S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 463 (04) : 551 - 556
  • [23] Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment
    Shalev, Nurit
    Kendall, Michelle
    Kumar, Navin
    Tiwari, Sudeep
    Anil, Seegehalli M.
    Hauschner, Hagit
    Swamy, Savvemala G.
    Doron-Faingenboim, Adi
    Belausov, Eduard
    Kendall, Bruce E.
    Koltai, Hinanit
    FRONTIERS IN GENETICS, 2024, 15
  • [24] Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib
    Zhang, Qi
    Xu, Yingkun
    Zhang, Zhiyu
    Li, Jianyi
    Xia, Qinghua
    Chen, Yougen
    GENE, 2021, 769
  • [25] Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer
    Zhang, Lan
    Zhen, Yongqi
    Feng, Lu
    Li, Zhijia
    Lu, Yingying
    Wang, Guan
    Ouyang, Liang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 259
  • [26] Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction
    Sang, Meixiang
    Meng, Lingjiao
    Ma, Cuicui
    Liu, Sihua
    Sang, Meijie
    Chang, Sheng
    Liu, Fei
    Lian, Yishui
    Geng, Cuizhi
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 111 : 169 - 177
  • [27] Effect of p53 Activity on the Sensitivity of Human Glioblastoma Cells to PARP-1 Inhibitor in Combination with Topoisomerase I Inhibitor or Radiation
    Sabbatino, Francesco
    Fusciello, Celeste
    Somma, Domenico
    Pacelli, Roberto
    Poudel, Ravin
    Pepin, David
    Leonardi, Antonio
    Carlomagno, Chiara
    Scarpati, Giuseppina Della Vittoria
    Ferrone, Soldano
    Pepe, Stefano
    CYTOMETRY PART A, 2014, 85A (11) : 953 - 961
  • [28] An antihypertensive drug-AT1 inhibitor attenuated BRCA development promoted by chronic psychological stress via Ang II/PARP1/FN1 pathway
    Cui, Yuqing
    Zhuang, Ming
    Huang, Zheping
    Guo, Yan
    Chen, Fengzhi
    Li, Yangyang
    Long, Yuanhui
    Liu, Ying
    Zeng, Guangchun
    Feng, Xujing
    Chen, Xuesong
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (03):
  • [29] E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
    McGonigle, Sharon
    Chen, Zhihong
    Wu, Jiayi
    Chang, Paul
    Kolber-Simonds, Donna
    Ackermann, Karen
    Twine, Natalie C.
    Shie, Jue-Lon
    Miu, Jingzang Tao
    Huang, Kuan-Chun
    Moniz, George A.
    Nomoto, Kenichi
    ONCOTARGET, 2015, 6 (38) : 41307 - 41323
  • [30] The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin
    Dellavedova, Giulia
    Decio, Alessandra
    Formenti, Laura
    Albertella, Mark R.
    Wilson, Joanne
    Staniszewska, Anna D.
    Leo, Elisabetta
    Giavazzi, Raffaella
    Ghilardi, Carmen
    Bani, Maria Rosa
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (03): : 489 - 500